SCHEMBL10313461

SCHEMBL10313461

Cc1ccc(-c2c(C)nn3c(=O)c(C)c(-c4ccc(C#N)cc4)[nH]c23)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC11A2 P49281 1/20 0.38
KDM1A O60341 1/20 0.38
CNR1 P21554 2/20 0.38
CRHR1 P34998 1/20 0.38
ALDH1A1 P00352 2/20 0.37
CYP2A6 P11509 1/20 0.37
PLAT P00750 2/20 0.37
POLB P06746 1/20 0.36
DHODH Q02127 1/20 0.35
PDE10A Q9Y233 1/20 0.35
PDE9A O76083 2/20 0.34
NTRK1 P04629 1/20 0.34
PIM1 P11309 1/20 0.34
ACVR1 Q04771 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
PDE1C Q14123 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10313592 0.92 SLC11A2 (0.42) SLC11A2CRHR1ALDH1A1PLATACVR1
SCHEMBL10276573 0.88 AR (0.43) SLC11A2CRHR1ALDH1A1PLATKDM4E
SCHEMBL10275278 0.88 KIF11 (0.43) SLC11A2CNR1CRHR1PLAT
SCHEMBL10313493 0.84 SLC34A1 (0.43) ALDH1A1PLATKDM4EMEN1GAA
SCHEMBL10313459 0.81 PDE2A (0.41) SLC11A2PLAT
SCHEMBL10275295 0.81 MAPK14 (0.37) KDM1ACRHR1MAPK14
SCHEMBL10275796 0.81 CYP3A4 (0.41) CNR1CRHR1ALDH1A1KDM4EMEN1
SCHEMBL10313504 0.80 CHEK1 (0.41) SLC11A2KDM1ACNR1CRHR1PLAT
SCHEMBL10313454 0.79 ALDH1A1 (0.41) SLC11A2KDM1ACNR1CRHR1ALDH1A1
SCHEMBL10313589 0.77 ALDH1A1 (0.48) ALDH1A1PLATKDM4EMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 SLC11A2 4127/4885KDM1A 3996/4885CNR1 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.